{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:37:55Z","timestamp":1789911475078,"version":"4.0.1"},"reference-count":131,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T00:00:00Z","timestamp":1509408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004532","name":"Japan International Cooperation Agency","doi-asserted-by":"publisher","award":["iCMOB\/05\/16"],"award-info":[{"award-number":["iCMOB\/05\/16"]}],"id":[{"id":"10.13039\/501100004532","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0186364","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T13:31:53Z","timestamp":1509456713000},"page":"e0186364","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6454-1613","authenticated-orcid":true,"given":"Reagan M.","family":"Mogire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoseah M.","family":"Akala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaline W.","family":"Macharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Juma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes C.","family":"Cheruiyot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Andagalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany A.","family":"El-Shemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Nyanjom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,31]]},"reference":[{"key":"ref1","article-title":"Der Internist","author":"GD Burchard","year":"2014"},{"key":"ref2","unstructured":"World Health Organisation. World malaria report. World Health Organiization. 2016. ISBN 9789241564106"},{"key":"ref3","unstructured":"World Health Organization, Others. WHO briefing on Malaria Treatment Guidelines and artemisinin monotherapies. Geneva WHO. 2006; 1\u201328. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/malaria\/docs\/Meeting_briefing19April.pdf\" xlink:type=\"simple\">http:\/\/apps.who.int\/malaria\/docs\/Meeting_briefing19April.pdf<\/ext-link>"},{"key":"ref4","first-page":"1084","article-title":"Antimalarial drug resistance","volume":"113","author":"NJ White","year":"2004","journal-title":"JClinInvest"},{"key":"ref5","first-page":"345","article-title":"The resistance gene in malaria parasite identified","volume":"106","author":"I Herlekar","year":"2014","journal-title":"Curr Sci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nrmicro3138","article-title":"Antimalarial drug discovery\u2014approaches and progress towards new medicines","volume":"11","author":"EL Flannery","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.01144-06","article-title":"High-throughput Plasmodium falciparum growth assay for malaria drug discovery","volume":"51","author":"ML Baniecki","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1128\/AAC.48.5.1803-1806.2004","article-title":"Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening","volume":"48","author":"M Smilkstein","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/infdis\/jir037","article-title":"A high-throughput screen targeting malaria transmission stages opens new avenues for drug development","volume":"203","author":"K Buchholz","year":"2011","journal-title":"J Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/AAC.50.4.1586-1589.2006","article-title":"New approach for high-throughput screening of drug activity on Plasmodium liver stages","volume":"50","author":"A Gego","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","first-page":"188","article-title":"Impact of high-throughput screening","volume":"10","author":"R Macarron","year":"2011","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"21847","DOI":"10.1074\/jbc.M501100200","article-title":"High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"280","author":"J Baldwin","year":"2005","journal-title":"J Biol Chem"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/med.10066","article-title":"Synthetic peroxides as antimalarizals","volume":"24","author":"Y Tang","year":"2004","journal-title":"Med Res Rev"},{"key":"ref14","first-page":"15","article-title":"The History of Antimalarial Drugs","author":"SR Meshnick","year":"2001","journal-title":"Antimalar Chemother Mech Action, Resist New Dir Drug Discov"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.30750\/ijpbr.1.2.11","article-title":"In-Silico Drug Design: A revolutionary approach to change the concept of current Drug Discovery Process","volume":"1","author":"L Boruah","year":"2013","journal-title":"Ijpbr"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/156802610790232251","article-title":"Successful applications of computer aided drug discovery: moving drugs from concept to the clinic","volume":"10","author":"TT Talele","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4155\/fmc.11.63","article-title":"Software and resources for computational medicinal chemistry","volume":"3","author":"C Liao","year":"2011","journal-title":"Future Med Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e1002178","DOI":"10.1371\/journal.ppat.1002178","article-title":"The next opportunity in anti-malaria drug discovery: The liver stage","volume":"7","author":"ER Derbyshire","year":"2011","journal-title":"PLoS Pathog"},{"key":"ref19","first-page":"6335","article-title":"Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias","volume":"9","author":"V Gandhi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e1002224","DOI":"10.1371\/journal.ppat.1002224","article-title":"Hostile takeover by plasmodium: Reorganization of parasite and host cell membranes during liver stage egress","volume":"7","author":"S Graewe","year":"2011","journal-title":"PLoS Pathog"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1475-2875-7-S1-S8","article-title":"The role of anti-malarial drugs in eliminating malaria","volume":"7","author":"NJ White","year":"2008","journal-title":"Malar J"},{"key":"ref22","first-page":"3","article-title":"Genome sequence of the human malaria parasite Plasmodium falciparum","volume":"419","author":"MJ Gardner","year":"2013"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/138955706775475957","article-title":"Drug Targets for Plasmodium falciparum: a post-genomic review\/survey","volume":"6","author":"I Yeh","year":"2006","journal-title":"Mini Rev Med Chem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"34827","DOI":"10.1074\/jbc.M114.615831","article-title":"The Heme Biosynthesis Pathway Is Essential for <italic>Plasmodium falciparum<\/italic> Development in Mosquito Stage but Not in Blood Stages","volume":"289","author":"H Ke","year":"2014","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1128\/EC.00264-13","article-title":"Type II fatty acid biosynthesis is essential for Plasmodium falciparum sporozoite development in the midgut of Anopheles mosquitoes","volume":"13","author":"BCL van Schaijk","year":"2014","journal-title":"Eukaryot Cell"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.celrep.2015.03.011","article-title":"Genetic investigation of tricarboxylic acid metabolism during the Plasmodium falciparum life cycle","volume":"11","author":"H Ke","year":"2015","journal-title":"Cell Rep"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molbiopara.2010.05.006","article-title":"The Kennedy phospholipid biosynthesis pathways are refractory to genetic disruption in Plasmodium berghei and therefore appear essential in blood stages","volume":"173","author":"S D\u00e9champs","year":"2010","journal-title":"Mol Biochem Parasitol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1177\/15648265070284S407","article-title":"Folic Acid Metabolism and Malaria","volume":"28","author":"J Metz","year":"2007","journal-title":"Food Nutr Bull"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/febs.13615","article-title":"Targeting glycolysis in the malaria parasite <italic>Plasmodium falciparum<\/italic>","volume":"283","author":"DD van Niekerk","year":"2016","journal-title":"FEBS J"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/iub.1047","article-title":"Glucose-6-phosphate metabolism in Plasmodium falciparum","volume":"64","author":"J Preuss","year":"2012","journal-title":"IUBMB Life"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Azin Nezami \u2021, Tooru Kimura \u00a7, Koushi Hidaka \u00a7, Aiko Kiso \u00a7, Jun Liu \u2016, Yoshiaki Kiso \u00a7, et al. High-Affinity Inhibition of a Family of Plasmodium falciparum Proteases by a Designed Adaptive Inhibitor\u2020. American Chemical Society; 2003; 10.1021\/BI034131Z","DOI":"10.1021\/bi034131z"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/AAC.50.2.639-648.2006","article-title":"Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria","volume":"50","author":"KT Andrews","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"453186","DOI":"10.1155\/2014\/453186","article-title":"Serine Proteases of Malaria Parasite Plasmodium falciparum: Potential as Antimalarial Drug Targets","volume":"2014","author":"A Alam","year":"2014","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2174\/156802610790725461","article-title":"Proteases of Plasmodium falciparum as Potential Drug Targets and Inhibitors Thereof","volume":"10","author":"C Wegscheid-Gerlach","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/1568005043480952","article-title":"Computer Assisted Searches for Drug Targets with Emphasis on Malarial Proteases and their Inhibitors","volume":"4","author":"Y Wang","year":"2004","journal-title":"Curr Drug Target -Infectious Disord"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1128\/AAC.47.12.3810-3814.2003","article-title":"Antimalarial activities of novel synthetic cysteine protease inhibitors","volume":"47","author":"BJ Lee","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1471-4922(02)02321-8","article-title":"Protein kinases as drug targets in parasitic protozoa","volume":"18","author":"C Doerig","year":"2002","journal-title":"Trends Parasitol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0165-6147(02)02071-0","article-title":"Pharmacological inhibitors of cyclin-dependent kinases","volume":"23","author":"M Knockaert","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.pt.2008.08.007","article-title":"Protein kinases of malaria parasites: an update","volume":"24","author":"C Doerig","year":"2008","journal-title":"Trends Parasitol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.4155\/fmc.12.183","article-title":"<italic>Plasmodium<\/italic> kinases as targets for new-generation antimalarials","volume":"4","author":"IS Lucet","year":"2012","journal-title":"Future Med Chem"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbapap.2003.11.021","article-title":"Protein kinases as targets for anti-parasitic chemotherapy","volume":"1697","author":"C Doerig","year":"2004","journal-title":"Biochim Biophys Acta\u2014Proteins Proteomics"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/187152610791163381","article-title":"Exploring Novel Targets for Antimalarial Drug Discovery: Plasmodial Protein Kinases","volume":"10","author":"D Jirage","year":"2010","journal-title":"Infect Disord\u2014Drug Targets"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.healthpol.2010.12.002","article-title":"The cost of drug development: A systematic review","volume":"100","author":"S Morgan","year":"2011","journal-title":"Health Policy (New York)"},{"key":"ref44","first-page":"1","article-title":"Repositioning drugs and biologics: retargeting old\/ existing drugs for potential new therapeutic applications","volume":"4","author":"BS Sekhon","year":"2013","journal-title":"J Pharm Educ Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s11095-011-0486-6","article-title":"Finding promiscuous old drugs for new uses","volume":"28","author":"S Ekins","year":"2011","journal-title":"Pharm Res"},{"key":"ref46","unstructured":"Matthews H. Accelerating antimalarial drug discovery through repositioning. 2013;"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1039\/c3mb25382a","article-title":"Network-based drug repositioning","volume":"9","author":"Zikai Wu","year":"2013","journal-title":"Mol Biosyst"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1475-2875-13-143","article-title":"Repositioning: the fast track to new anti-malarial medicines?","volume":"13","author":"J Lotharius","year":"2014","journal-title":"Malar J"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijpddr.2015.05.004","article-title":"Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites","volume":"5","author":"JA Engel","year":"2015","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio806","article-title":"A clinical drug library screen identifies astemizole as an antimalarial agent (supplemental file: figure 1)","volume":"2","author":"CR Chong","year":"2006","journal-title":"Nat Chem Biol"},{"key":"ref51","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/0bbd3579-5212-4dcf-a5ef-dd3d8e26f287","article-title":"A Systematic In Silico Search for Target Similarity Identifies Several Approved Drugs with Potential Activity against the Plasmodium falciparum Apicoplast","volume":"8","author":"NA Bispo","year":"2013","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e3435","DOI":"10.1371\/journal.pntd.0003435","article-title":"In Silico Repositioning-Chemogenomics Strategy Identifies New Drugs with Potential Activity against Multiple Life Stages of Schistosoma mansoni","volume":"9","author":"BJ Neves","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"D61","DOI":"10.1093\/nar\/gkl842","article-title":"NCBI reference sequences (RefSeq): A curated non-redundant sequence database of genomes, transcripts and proteins","volume":"35","author":"KD Pruitt","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"ref54","unstructured":"Team RDC. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing. Vienna, Austria; 2004. citeulike-article-id:708579"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"D1035","DOI":"10.1093\/nar\/gkq1126","article-title":"DrugBank 3.0: A comprehensive resource for \u201cOmics\u201d research on drugs","volume":"39","author":"C Knox","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"D1128","DOI":"10.1093\/nar\/gkr797","article-title":"Therapeutic target database update 2012: A resource for facilitating target-oriented drug discovery","volume":"40","author":"F Zhu","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"D876","DOI":"10.1093\/nar\/gkr1011","article-title":"STITCH 3: Zooming in on protein-chemical interactions","volume":"40","author":"M Kuhn","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref58","unstructured":"T D R Targets. The TDR Targets Database v5 [Internet]. 2015 [cited 14 Dec 2015] pp. 1\u20135. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.tdrtargets.org\" xlink:type=\"simple\">http:\/\/www.tdrtargets.org<\/ext-link>"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"D1118","DOI":"10.1093\/nar\/gkr1053","article-title":"TDR targets: A chemogenomics resource for neglected diseases","volume":"40","author":"MP Magari\u00f1os","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrd2275","article-title":"Determining druggability","volume":"6","author":"J Owens","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: A large-scale bioactivity database for drug discovery","volume":"40","author":"A Gaulton","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","article-title":"Basic local alignment search tool","volume":"215","author":"SF Altschul","year":"1990","journal-title":"J Mol Biol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/bioinformatics\/19.1.163","article-title":"ConSurf: Identification of functional regions in proteins by surface-mapping of phylogenetic information","volume":"19","author":"F Glaser","year":"2003","journal-title":"Bioinformatics"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"D204","DOI":"10.1093\/nar\/gku989","article-title":"UniProt: A hub for protein information","volume":"43","author":"A Bateman","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"D445","DOI":"10.1093\/nar\/gkr998","article-title":"PDBe: Protein Data Bank in Europe","volume":"40","author":"S Velankar","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/bioinformatics\/bti770","article-title":"The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling","volume":"22","author":"K Arnold","year":"2006","journal-title":"Bioinformatics"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/AAC.01607-06","article-title":"Assessment and continued validation of the malaria SYBR Green I-based fluorescence assay for use in malaria drug screening","volume":"51","author":"JD Johnson","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1128\/AAC.00527-15","article-title":"Assessment of the Worldwide antimalarial resistance network standardized procedure for in vitro malaria drug sensitivity testing using SYBR green assay for field samples with various initial parasitemia levels","volume":"60","author":"AC Cheruiyot","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4269\/ajtmh.2011.10-0674","article-title":"Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR green I in vitro assay and molecular analysis","volume":"85","author":"HM Akala","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7883\/yoken1952.47.241","article-title":"Cure With Cisplatin (Ii) of Murine Malaria Infection and in Vitro Inhibition of a Chloroquine-Resistant Plasmodium Falciparum Isolate","volume":"47","author":"L Nair","year":"1994","journal-title":"Japanese J Med Sci Biol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0006-2952(94)90279-8","article-title":"Roles of peptidyl-prolyl CIS-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin a, FK506, and rapamycin","volume":"48","author":"A Bell","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/AAC.40.2.358","article-title":"In vitro and in vivo inhibition of erythrocytic development of malarial parasites by docetaxel","volume":"40","author":"V Sinou","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"ref73","first-page":"552","article-title":"Lack of in vitro effect of ivermectin on Plasmodium falciparum","volume":"34","author":"P Nasveld","year":"2003","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1128\/AAC.05130-11","article-title":"In vitro activity of antiretroviral drugs against Plasmodium falciparum","volume":"55","author":"C Nsanzabana","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1128\/AAC.47.8.2636-2639.2003","article-title":"In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp","volume":"47","author":"N Mahmoudi","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1128\/AAC.36.8.1644","article-title":"In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents","volume":"36","author":"D Figgitt","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/infdis\/164.3.602","article-title":"Ciprofloxacin treatment of drug-resistant falciparum malaria","volume":"164","author":"G Dennis Shanks","year":"1991","journal-title":"J Infect Dis"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.01330-06","article-title":"Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum [3]","volume":"51","author":"B Pradines","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0001-706X(99)00051-0","article-title":"In vitro antimalarial activity of trovafloxacin, a fourth-generation fluoroquinolone","volume":"74","author":"J Hamzah","year":"2000","journal-title":"Acta Trop"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0020-7519(00)00043-6","article-title":"Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents","volume":"30","author":"KT Andrews","year":"2000","journal-title":"Int J Parasitol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2875-8-102","article-title":"Azathioprine favourably influences the course of malaria","volume":"8","author":"D Bobbala","year":"2009","journal-title":"Malar J"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/1475-2875-13-476","article-title":"In vitro activity of immunosuppressive drugs against Plasmodium falciparum","volume":"13","author":"L Veletzky","year":"2014","journal-title":"Malar J"},{"key":"ref83","article-title":"The antiplasmodial activity of norcantharidin analogs","author":"J Bajsa","year":"2010","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s00436-002-0690-8","article-title":"Effects of dipyridamole on Plasmodium falciparum-infected erythrocytes","volume":"88","author":"M Akaki","year":"2002","journal-title":"Parasitol Res"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1590\/S0074-02762002000700018","article-title":"In vitro chloroquine resistance modulation study on fresh isolates of Brazilian Plasmodium falciparum: Intrinsic antimalarial activity of phenothiazine drugs","volume":"97","author":"CMS Menezes","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/1471-2105-8-353","article-title":"Prediction of potential drug targets based on simple sequence properties","volume":"8","author":"Q Li","year":"2007","journal-title":"BMC Bioinformatics"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"e1001169","DOI":"10.1371\/journal.pmed.1001169","article-title":"The activities of current antimalarial drugs on the life cycle stages of plasmodium: A comparative study with human and rodent parasites","volume":"9","author":"M Delves","year":"2012","journal-title":"PLoS Med"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/IAI.69.3.1536-1546.2001","article-title":"Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial","volume":"69","author":"AW Stowers","year":"2001","journal-title":"Infect Immun"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","author":"EM Leslie","year":"2005","journal-title":"Toxicology and Applied Pharmacology"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1042\/bse0500121","article-title":"ABC transporters involved in drug resistance in human parasites","volume":"50","author":"P Leprohon","year":"2011","journal-title":"Essays Biochem"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.pt.2010.05.002","article-title":"The ABCs of multidrug resistance in malaria","volume":"26","author":"JB Koenderink","year":"2010","journal-title":"Trends Parasitol"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1074\/jbc.M806944200","article-title":"Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione","volume":"284","author":"DK Raj","year":"2009","journal-title":"J Biol Chem"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/mmi.13373","article-title":"Vital and dispensable roles of Plasmodium multidrug resistance transporters during blood- and mosquito-stage development","volume":"101","author":"SR Rijpma","year":"2016","journal-title":"Mol Microbiol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1128\/IAI.72.12.6757-6763.2004","article-title":"ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies","volume":"72","author":"HS Garmory","year":"2004","journal-title":"Infect Immun"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"EY Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","article-title":"Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells","volume":"11","author":"FM Johnson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","article-title":"Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\u201ctriple-negative\u201d breast cancer cell lines growing in vitro","volume":"105","author":"RS Finn","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd2132","article-title":"Drugs, their targets and the nature and number of drug targets","volume":"5","author":"P Imming","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/14796694.2.6.655","article-title":"Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib","volume":"2","author":"A Quint\u00e1s-Cardama","year":"2006","journal-title":"Futur Oncol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1158\/1535-7163.MCT-06-0382","article-title":"Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib","volume":"5","author":"A Serrels","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL","volume":"61","author":"AV Kamath","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1021\/jm060727j","article-title":"2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure\u2212Activity Relationship Studies toward the Discovery of <italic>N<\/italic> -(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent <italic>pan<\/italic> -Src Kinase Inhibitor","volume":"49","author":"J Das","year":"2006","journal-title":"J Med Chem"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib","volume":"38","author":"M Dohse","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"C Heged\u0171s","year":"2009","journal-title":"Br J Pharmacol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0164895","article-title":"Inhibition of an erythrocyte tyrosine kinase with imatinib prevents Plasmodium falciparum egress and terminates parasitemia","volume":"11","author":"KR Kesely","year":"2016","journal-title":"PLoS One"},{"key":"ref106","first-page":"6872","article-title":"Synthesis of 5???-methylthio coformycins: Specific inhibitors for malarial adenosine deaminase","volume":"129","author":"PC Tyler","year":"2007","journal-title":"J Am Chem Soc"},{"key":"ref107","first-page":"13","article-title":"Adenosine deaminase from Plasmodium falciparum as a Potential Drug Target in Anti- Malarial Drug Designing: A Bioinformatic Approach","author":"S Sriram","year":"2009","journal-title":"Africa (Lond)"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"9547","DOI":"10.1074\/jbc.M412693200","article-title":"Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins","volume":"280","author":"LM Ting","year":"2005","journal-title":"J Biol Chem"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00003495-199447040-00008","article-title":"Levofloxacin: A Review of its Antibacterial Activity, Pharmacokinetics and Therapeutic Efficacy","volume":"47","author":"R Davis","year":"1994","journal-title":"Drugs"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/.61.3.377-392.1997","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones","volume":"61","author":"K Drlica","year":"1997","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA Topoisomerases: Structure, Function, and Mechanism","volume":"70","author":"JJ Champoux","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1098\/rspb.2009.2176","article-title":"DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery","volume":"277","author":"C Garcia-Estrada","year":"2010","journal-title":"Proc Biol Sci"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0006-2952(97)00556-X","article-title":"Effects of camptothecin, a topoisomerase I inhibitor, on Plasmodium falciparum","volume":"55","author":"AL Bodley","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ptr.2860","article-title":"The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells","volume":"24","author":"Y Ma","year":"2010","journal-title":"Phyther Res"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2174\/156802609788085313","article-title":"Targeting Histone Deacetylase Inhibitors for Anti-Malarial Therapy","volume":"9","author":"K Andrews","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/icb.2011.97","article-title":"HDAC inhibitors in parasitic diseases","volume":"90","author":"KT Andrews","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"ref117","first-page":"13143","article-title":"Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase (cyclic <styled-content><inline-formula id=\"pone.0186364.e001\"><alternatives><graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" id=\"pone.0186364.e001g\" mimetype=\"image\" position=\"anchor\" xlink:href=\"info:doi\/10.1371\/journal.pone.0186364.e001\" xlink:type=\"simple\"><\/graphic><mml:math display=\"inline\" id=\"M1\"><mml:mrow><mml:mi mathvariant=\"normal\">tetrapeptid<\/mml:mi><mml:mover accent=\"true\"><mml:mrow><mml:mi mathvariant=\"normal\">eA<\/mml:mi><\/mml:mrow><mml:mo stretchy=\"true\">\u00af<\/mml:mo><\/mml:mover><mml:mi mathvariant=\"normal\">picomplex<\/mml:mi><mml:mover accent=\"true\"><mml:mrow><mml:mi mathvariant=\"normal\">aa<\/mml:mi><\/mml:mrow><mml:mo stretchy=\"true\">\u00af<\/mml:mo><\/mml:mover><mml:mi mathvariant=\"normal\">ntiparasiti<\/mml:mi><mml:mover accent=\"true\"><mml:mrow><mml:mi mathvariant=\"normal\">cm<\/mml:mi><\/mml:mrow><mml:mo stretchy=\"true\">\u00af<\/mml:mo><\/mml:mover><mml:mi mathvariant=\"normal\">alari<\/mml:mi><mml:mover accent=\"true\"><mml:mrow><mml:mi mathvariant=\"normal\">ac<\/mml:mi><\/mml:mrow><mml:mo stretchy=\"true\">\u00af<\/mml:mo><\/mml:mover><mml:mi mathvariant=\"normal\">occidiosis<\/mml:mi><\/mml:mrow><\/mml:math><\/alternatives><\/inline-formula><\/styled-content>)","volume":"93","author":"SJ Darkin-Rattray","year":"1996","journal-title":"Med Sci"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1021\/cr990097b","article-title":"Mycophenolic acid: A one hundred year odyssey from antibiotic to immunosuppressant","volume":"100","author":"R Bentley","year":"2000","journal-title":"Chem Rev"},{"key":"ref119","first-page":"403","article-title":"Recent development of IMP dehydrogenase inhibitors for the treatment of cancer","volume":"10","author":"L Chen","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/095632020101200501","article-title":"Mechanisms of action of ribavirin in antiviral therapies","volume":"12","author":"RC Tam","year":"2001","journal-title":"Antivir Chem Chemother"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2174\/092986711795590129","article-title":"The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors","volume":"18","author":"L Hedstrom","year":"2011","journal-title":"Curr Med Chem"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): molecular and cellular mechanisms","volume":"17","author":"AW Thomson","year":"1995","journal-title":"Ther Drug Monit"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molbiopara.2004.10.007","article-title":"A Plasmodium falciparum FK506-binding protein (FKBP) with peptidyl\u2013prolyl cis\u2013trans isomerase and chaperone activities","volume":"139","author":"P Monaghan","year":"2005","journal-title":"Mol Biochem Parasitol"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/imm.12661","article-title":"Tacrolimus prevents murine cerebral malaria","volume":"150","author":"LQ Bao","year":"2017","journal-title":"Immunology"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1124\/mol.105.020172","article-title":"Potent Inhibition of Platelet-Derived Growth Factor-Induced Responses in Vascular Smooth Muscle Cells by BMS-354825 (Dasatinib)","volume":"69","author":"Z Chen","year":"2006","journal-title":"Mol Pharmacol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1124\/dmd.107.020255","article-title":"Identification of the Human Enzymes Involved in the Oxidative Metabolism of Dasatinib: An Effective Approach for Determining Metabolite Formation Kinetics","volume":"36","author":"L Wang","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate-Sensitive or Imatinib Mesylate-Resistant Chronic Myelogenous Leukemia Cells","volume":"12","author":"W Fiskus","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"NP van Erp","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: the network approach might help drug design","volume":"26","author":"P Csermely","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jama.292.4.419","article-title":"\u201cPromiscuous\u201d Anticancer Drugs That Hit Multiple Targets May Thwart Resistance","volume":"292","author":"T Hampton","year":"2004","journal-title":"Jama"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"GR Zimmermann","year":"2007","journal-title":"Drug Discov Today"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0186364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T18:13:35Z","timestamp":1603217615000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0186364"}},"subtitle":[],"editor":[{"given":"Stuart Alexander","family":"Ralph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,31]]},"references-count":131,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0186364","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732056967.793538700","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,31]]}}}